

# MEDX xelerator

## \$3.5M Round A



CAPS MEDICAL closed a \$3.5 million A Round & is scaling up

[Read more](#)

## \$7.4M Round A



Append Medical closed a \$7.4M A round - led by a major strategic vascular company

[Read more](#)

## First M&A



ENDOWAYS LTD acquired by Ascendum less than 3 years after inception

[Read more](#)

## \$1.3M SAFE



EXERO MEDICAL closed a \$1.3 million SAFE

[Read more](#)

## A new partner



CBG, a British investment firm, partners with MEDX

[Read more](#)

## Collaboration with pharma giant



West Pharmaceuticals collaborates on drug delivery devices

[Read more](#)

## Collaboration with Sheba Medical Center



Joint development of solutions for clinical unmet needs

[Read more](#)

## 2021 investments



Four new companies created

[Read more](#)

## Ongoing \$1M Challenge



Interventional oncology challenge chaired by Prof. Stephen B. Solomon

[Read more](#)

## The incubator facilities are growing



Additional 400 sqm for mature company expansion

[Read more](#)

## With 2022 quickly approaching, we look back on what has been a pivotal year for MEDX. Here are some of the highlights.



### **Our first cohort of companies successfully graduated.**

All four companies successfully achieved their milestones. [Endoways completed an M&A](#) and the three other raised series A.



### **We increased our global network of collaborations with new partners CBG and West.**

Consensus Business Group (CBG), a British investment firm owned by entrepreneur Vincent Tchenguiz, [joined the incubator as a partner](#). MEDX announced a [collaboration with West Pharmaceuticals](#) with the goal of supporting entrepreneurs with excellent ideas for new drug delivery devices.



### **We established a new collaboration.**

MEDX is collaborating with Sheba Medical Center (the largest hospital in Israel) to develop new opportunities for unmet clinical needs.



## Our Latest Four Seed Investments



**VeinWay** is developing a dedicated solution for treating chronic venous blockages intended to help physicians cross complex occlusions and shorten procedure time. VeinWay is a product of the Entrepreneur-in-Residence Program at MEDX Xelerator, which supports new technologies that address significant unmet clinical needs identified in collaboration with physicians and strategic partners.

VeinWay won third prize in the prestigious \$1 million Dongsheng competition in China with more than 2000 applicants.



**EyeMed** is developing premium lenses for intraocular implantation that will allow vision to be adjusted in a non-invasive procedure after cataract surgery. Fifty percent of cataract surgeries using premium lenses today are not able to achieve perfect vision.



**BeWeld** is developing a technology to automate the manufacturing processes of implantable devices.

**NewCo** is developing a technology for treating PAD patients.

## Portfolio Company Milestones



**APPEND MEDICAL** Append Medical closed a \$7.4M A round. The round will enable Append Medical to complete development and perform its first clinical trial of the first no-implant minimally invasive solution for transcatheter Left Atrial Appendage (LAA). Append, a mature portfolio company, is moving into the new 400 sqm space at MEDX Xelerator.



**EXERO MEDICAL** closed a \$1.3 million SAFE and was granted a US and Chinese patent for its wireless system for the early detection of anastomotic leaks (AL) following gastrointestinal (GI) surgery. Exero's Smart Drainage system received Breakthrough Designation status from the FDA. The company also completed first in human trials. Exero, a mature portfolio company, is moving into the new 400 sqm space at MEDX Xelerator.



Promising interim results for **PATENSEE** in its clinical trial. Led by Professor Benaya Rozen-Zvi, director of the Institute for Nephrology and Hypertension at Rabin Medical Center, the study is evaluating the ability of PatenSee's imaging surveillance system for hemodialysis patients to perform contact-free surveillance of fistula stenosis, similar to a nurse's physical exam. The results will be presented at WCN, the primary global nephrology conference, February 24-27, 2022.



Great interim results for Synchrony Medical in its first clinical trial using LibAirty™, a next generation, home-use, airway clearance system in clinical development to help patients with chronic lung disease maintain clear lungs with a short, daily, proficient treatment.

## Top Three In-House Activities

As part of our initiative to provide better, quicker and more capital efficient support to our portfolio companies, we added two new positions to our capable team: A business development analyst and an in-house IP Expert.

In December 2021, MEDX commenced an [interventional oncology challenge](#) chaired by Professor Stephen B. Solomon is ongoing. It's a \$1M challenge for pre-seed projects as well as seed start-ups and Round A companies.

The incubator is also actively recruiting [excellent professionals to lead](#) existing and future portfolio companies.

In between covid and clinical trials we found the time to row in the Jordan river 😊



It is our intention to continue as well as increase the strong momentum generated in 2021 in the coming year.

We want to thank our investors, partners and collaborators:



We are wishing you and yours the very best for a happy, healthy and successful 2022!

CHEERS!

**Season's Greetings!**

The MEDX Xelerator Team



FOR THE LATEST NEWS, FOLLOW MEDX ON LINKEDIN. CLICK:

